Back

External Validation of HASBLED and ORBIT bleeding risk scores in Wales-AF population

26 August 2023 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk assessment: scores (2) Scores ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mrs Fatemeh TORABI

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
AF in TAVR patients: double trouble means double care
Doctor C. Oliveira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Validation of the PRECISE-DAPT score in a population-based sample of patients undergoing percutaneous coronary intervention with stent implantation
Mr C. Lim (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Improving risk stratification of recurrent myocardial infarction in a large real-world dataset using machine learning
Professor Z. Vered (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Clinician-reported EHRA and NYHA scores only moderately reflect patient-reported quality of life in atrial fibrillation and heart failure
Doctor J. Van De Pol (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
Utility of a polygenic risk score for incident CHD: interplay with lifestyle in a multi-ethnic cohort of more than 60,000 individuals
Doctor C. Iribarren (Oakland, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular risk assessment: scores (2)

The Event

Event poster

ESC Congress 2023

26 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Predicting bleeding risk in frail older patients with atrial fibrillation using data from the FRAIL-AF trial
thumbnail
Congress Presentation
Evaluation of the biomarker-based ABC-AF-bleeding risk score and clinically based bleeding scores in 31,605 patients with atrial fibrillation treated with oral anticoagulation
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources